Antisense Oligonucleotide and RNA Therapies for Neurodegeneration

Antisense Oligonucleotide and RNA Therapies for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotide and RNA Therapies for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Modification</td>
<td>Description</td>
</tr>
<tr>
<td class="label">2'-O-Methyl (2'-OMe)</td>
<td>Ribose sugar modification</td>
</tr>
<tr>
<td class="label">2'-O-Methoxyethyl (2'-MOE)</td>
<td>Extended sugar modification</td>
</tr>
<tr>
<td class="label">Locked Nucleic Acid (LNA)</td>
<td>Constrained sugar conformation</td>
</tr>
<tr>
<td class="label">Phosphorodiamidate Morpholino Oligomer (PMO)</td>
<td>Uncharged backbone</td>
</tr>
<tr>
<td class="label">2'-Deoxy, 2'-Fluoro</td>
<td>Sugar modification</td>
</tr>
<tr>
<td class="label">Phosphorothioate (PS)</td>
<td>Backbone modification</td>
</tr>
<tr>
<td class="label">Conjugated peptides (Peptide Nucleic Acid - PNA)</td>
<td>Backbone replacement</td>
</tr>
</table>

Overview

Antisense Oligonucleotide and RNA Therapies for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotide and RNA Therapies for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Modification</td>
<td>Description</td>
</tr>
<tr>
<td class="label">2'-O-Methyl (2'-OMe)</td>
<td>Ribose sugar modification</td>
</tr>
<tr>
<td class="label">2'-O-Methoxyethyl (2'-MOE)</td>
<td>Extended sugar modification</td>
</tr>
<tr>
<td class="label">Locked Nucleic Acid (LNA)</td>
<td>Constrained sugar conformation</td>
</tr>
<tr>
<td class="label">Phosphorodiamidate Morpholino Oligomer (PMO)</td>
<td>Uncharged backbone</td>
</tr>
<tr>
<td class="label">2'-Deoxy, 2'-Fluoro</td>
<td>Sugar modification</td>
</tr>
<tr>
<td class="label">Phosphorothioate (PS)</td>
<td>Backbone modification</td>
</tr>
<tr>
<td class="label">Conjugated peptides (Peptide Nucleic Acid - PNA)</td>
<td>Backbone replacement</td>
</tr>
</table>

Overview

Antisense oligonucleotides (ASOs) and RNA-based therapies represent a transformative approach to treating the underlying genetic and neurodegenerative diseases by targeting molecular causes of these conditions. These therapies work by modulating RNA expression, either by degrading disease-causing mRNA, correcting aberrant splicing, or blocking translation of toxic proteins. This page provides a comprehensive overview of ASO and RNA therapy mechanisms, clinical candidates, and therapeutic applications for Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative disorders.

Mechanism of Action

Antisense oligonucleotides are short, synthetic single-stranded DNA sequences designed to bind specifically to target messenger RNA (mRNA) through Watson-Crick base pairing. Once bound, ASOs employ several distinct mechanisms to modulate gene expression:

RNase H-Mediated Degradation

The most common mechanism involves recruitment of RNase H, an endonuclease that specifically cleaves the RNA strand of RNA-DNA hybrids. When an ASO binds to its target mRNA, RNase H recognizes the hybrid duplex and cleaves the RNA, leading to rapid degradation of the transcript. This mechanism is particularly effective for reducing expression of gain-of-function mutations or overexpressed disease proteins.

Splice Modulation

ASOs can also modulate alternative splicing by binding to pre-mRNA and sterically blocking splice site recognition. This approach is valuable for diseases where aberrant splicing produces toxic protein isoforms. By masking or exposing specific splice sites, ASOs can restore normal splicing patterns or shift isoform ratios toward protective variants.

Steric Block Translation Arrest

Some ASOs function as steric blocks without recruiting RNase H. These "gapmer" ASOs bind to mRNA and physically prevent ribosomes from translating the transcript into protein. This mechanism is useful when partial reduction of protein expression is desired.

Chemical Modifications

The clinical utility of ASOs depends heavily on chemical modifications that enhance stability, tissue delivery, and target affinity while minimizing off-target effects:

Clinical Applications in Neurodegeneration

Amyotrophic Lateral Sclerosis (ALS)

Tofersen (BIIB067)

Tofersen is an ASO designed to reduce superoxide dismutase 1 (SOD1) protein expression in patients with SOD1-linked familial ALS. The therapy binds to SOD1 mRNA, leading to RNase H-mediated degradation and subsequent reduction in toxic SOD1 protein[@kankowski2023][@bennett2022].

Clinical Development:

• Phase 1/2 study showed dose-dependent reduction in SOD1 protein in cerebrospinal fluid[@kankowski2023]
• Phase 3 VALOR trial met its primary endpoint of change in ALS Functional Rating Scale-Revised (ALSFRS-R) at higher doses[@bennett2022]
• Received accelerated FDA approval in 2024 for SOD1-ALS

ION363 (Jacifusen)

ION363 targets the gene encoding fused in sarcoma (FUS) protein, which is mutated in some cases of familial ALS. By reducing FUS protein expression, this ASO aims to prevent FUS-related neurodegeneration.

Clinical Status: Phase 1/2 trials ongoing

Alzheimer's Disease

ION717 (tau-ASO)

ION717 is an ASO targeting [MAPT](/proteins/tau) mRNA, which encodes the tau protein that forms neurofibrillary tangles in Alzheimer's disease. By reducing tau expression, this therapy aims to slow or prevent tau-mediated neuronal death[@aso][@finkel2017].

Development:

• Investigational new drug (IND) application cleared by FDA
• Phase 1 clinical trial initiated by Ionis Pharmaceuticals in partnership with Roche
• Targets both sporadic and familial AD

IONIS-MAPTRx

This is another tau-targeting ASO from Ionis that uses their advanced chemistry platform for enhanced brain delivery. The therapy is designed to reduce all forms of tau protein[@aso][@finkel2017].

Huntington's Disease

Tominersen (RG6042)

Originally developed by Ionis and later partnered with Roche, tominersen targets the huntingtin (HTT) gene to reduce mutant [huntingtin protein](/proteins/huntingtin). Although the Phase 3 GENERATION HD1 trial was discontinued due to unfavorable risk-benefit profile, the program provided valuable lessons about ASO dosing and delivery[@sullivan2021].

Parkinson's Disease

ASO approaches for Parkinson's disease target genes implicated in disease pathogenesis, including:

• LRRK2: Targeting the leucine-rich repeat kinase 2 gene
• SNCA: Reducing [alpha-synuclein](/proteins/alpha-synuclein) expression
• GBA1: Modulating glucocerebrosidase expression

siRNA Therapies

Small interfering RNA (siRNA) molecules trigger the RNA interference (RNAi) pathway, leading to sequence-specific mRNA degradation. Unlike ASOs, siRNAs require delivery vehicles for cellular uptake.

Alnylam Platform

Alnylam Pharmaceuticals has developed a proprietary GalNAc conjugation platform that enables subcutaneous delivery of siRNA to target hepatocytes. For CNS applications, the company is exploring:

• Direct intrathecal delivery
• Novel conjugation strategies for brain targeting
• Combination with focused ultrasound for [BBB](/entities/blood-brain-barrier) opening

Clinical Candidates

Several siRNA programs targeting neurodegenerative disease genes are in development, though none have reached late-stage clinical trials for CNS indications as of 2024.

mRNA Therapies

mRNA-based therapeutics offer the potential to deliver genetic instructions for therapeutic protein expression directly to cells. Applications in neurodegeneration include:

Protein Replacement

Delivering mRNA encoding missing or deficient proteins:

• AADC deficiency: Aromatic L-amino acid decarboxylase
• GDNF delivery: Glial cell line-derived neurotrophic factor

Antibody Production

mRNA encoding therapeutic antibodies can be delivered to produce antibodies in vivo:

• Anti-amyloid antibodies
• Anti-tau antibodies
• Neuroprotective factors

Advantages and Challenges

Advantages:

• Transient protein expression
• No genomic integration risk
• Scalable manufacturing

• Immune response to mRNA
• Delivery across the blood-brain barrier
• Durability of expression

CRISPR and Gene Editing Approaches

While not traditional RNA therapies, CRISPR-based approaches represent the next frontier in nucleic acid-based therapeutics:

Base Editing

Base editors enable single-nucleotide changes without double-strand breaks:

• Correction of disease-causing point mutations
• Disruption of toxic protein expression
• Epigenetic modifications

Prime Editing

Prime editing offers greater flexibility for precise genome modifications, including insertions and deletions.

Delivery Challenges

CNS delivery remains the major hurdle for CRISPR-based therapies

Delivery Strategies

Intrathecal Delivery

The most common route for CNS-directed ASOs, intrathecal injection delivers therapy directly to the cerebrospinal fluid, bypassing the blood-brain barrier:

Approved Examples:

• Nusinersen (Spinraza) for spinal muscular atrophy
• Tofersen for SOD1-ALS

• Requires lumbar puncture
• Distribution limited to spinal cord and some brain regions
• Repeated dosing necessary

Intranasal Delivery

Non-invasive approach that exploits the nose-to-brain pathway:

• Direct transport along olfactory nerve
• Bypasses BBB
• Currently experimental for ASOs

Conjugated and Engineered Delivery

• GalNAc conjugates: Liver targeting (not brain)
• Cell-penetrating peptides: Enhanced cellular uptake
• Antibody-mediated delivery: Receptor-mediated transcytosis

Focused Ultrasound

Combining ASO delivery with focused ultrasound-mediated BBB opening shows promise for enhancing brain penetration[@miller2023].

Companies and Pipeline

Ionis Pharmaceuticals

Leading developer of ASO therapies with multiple programs in neurodegeneration:

• Tofersen (with Biogen): FDA approved for SOD1-ALS
• ION717 (with Roche): Phase 1 for Alzheimer's disease
• IONIS-MAPTRx: Preclinical/early clinical
• Multiple early-stage programs

Biogen

Partnered with Ionis on several CNS ASO programs:

• Tofersen: Commercial and clinical development
• ION451: Targeting LRRK2 for Parkinson's disease

Roche

Major partnership with Ionis for neurological disorders:

• ION717 (tau-ASO)
• Tominersen (Huntington's disease)

Alnylam

siRNA platform with growing CNS pipeline:

• Early-stage programs for neurodegenerative diseases
• GalNAc platform expanded for CNS delivery

Emerging Companies

• Wave Life Sciences: Stereopure ASOs with enhanced properties
• Dicerna Pharmaceuticals: GalNAc-siRNA platform
• NeuBase Therapeutics: PATency-enhanced ASOs

Future Directions

Next-Generation Chemistry

• Enhanced blood-brain barrier penetration
• Reduced off-target effects
• Improved durability of effect
• Tissue-specific targeting

Combination Approaches

• ASO plus small molecule therapy
• Gene therapy combinations
• Immunomodulatory strategies

Biomarker Development

• CSF tau reduction as biomarker
• Neurofilament light chain (NfL) as marker of neuronal injury
• PET imaging for target engagement

Challenges and Limitations

Blood-Brain Barrier

The BBB remains the primary challenge for CNS-directed RNA therapies. Strategies under development include:

• Focused ultrasound-mediated opening
• Receptor-mediated transcytosis
• Intranasal delivery optimization
• Novel conjugation strategies

Safety Concerns

• Off-target effects
• Immune stimulation
• CNS inflammation
• Long-term safety unknown

Manufacturing and Cost

• Complex synthesis and purification
• High development costs
• Accessibility and reimbursement challenges

Conclusion

Antisense oligonucleotide and RNA therapies represent a promising new frontier in neurodegenerative disease treatment. With the recent approval of tofersen for SOD1-ALS and multiple programs advancing in Alzheimer's, Parkinson's, and other disorders, these therapies are moving from promise to reality. Continued advances in chemistry, delivery technology, and biomarker development will be critical for realizing the full potential of RNA-based therapeutics for neurodegenerative diseases.

See Also

• [Gene Therapy for Neurodegeneration](/investment/gene-therapy-neurodegeneration)
• [CNS Drug Delivery Methods](/mechanisms/cns-drug-delivery-methods)
• [Blood-Brain Barrier Biology](/mechanisms/blood-brain-barrier)
• [Tau Pathology Mechanisms](/content/mechanisms)
• [RNA Metabolism in Neurodegeneration](/mechanisms/rna-metabolism)
• [ASO Brain Delivery](/therapeutics/aso-brain-delivery)

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov/)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [DrugBank](https://go.drugbank.com/)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;